Commercial Insight: Multiple Sclerosis - Next Generation Therapies Signal the Start of a New Era by Datamonitor Now Available at ReportsandReports

With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy.

Dallas, TX, August 13, 2010 --(PR.com)-- ReportsandReports Announce it Will Carry Commercial Insight: Multiple Sclerosis - Next generation therapies signal the start of a new era Market Research Report in its Store.

Browse the complete Report on: http://www.reportsandreports.com/market-reports/commercial-insight-multiple-sclerosis-next-generation-therapie/

With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (20092019).

Scope
- In-depth analysis of the current and future multiple sclerosis therapies across the US, Japan, France, Germany, Italy, Spain and the UK.
- Country-specific total brand sales forecasts for key products, biosimilars and pipeline agents across the seven major markets to 2019.
- Assessment of the commercial opportunities and threats present in the multiple sclerosis market, with analysis of trends in emerging markets.
- Evaluation of the strategies of leading players in the multiple sclerosis disease market.

Highlights
Datamonitor expects Novartis's Gilenia (fingolimod) to launch at the end of 2010 as a first-line therapy, while Merck Serono's oral cladribine is anticipated to launch at the start of 2011. These drugs offer improved efficacy and a less invasive method of administration than current treatments.

Datamonitor expects entry of biosimilar drugs from 2014. The introduction of cost competition will force current market players to cease raising the price of their drugs above the norm; a strategy that has helped them to substantially increase revenues in recent years.

Browse all Healthcare at http://www.reportsandreports.com/market-research/healthcare/

Browse all Datamonitor at http://www.reportsandreports.com/Publishers/datamonitor

Browse Latest Reports at: http://www.reportsandreports.com/LatestReport.aspx

Related Reports:

GCC District Cooling: the start of a new era
http://www.reportsandreports.com/market-reports/gcc-district-cooling-the-start-of-a-new-era/

Pipeline Insight: Biologic Targeted Cancer Therapies - Next generation jostles for market position
http://www.reportsandreports.com/market-reports/pipeline-insight-biologic-targeted-cancer-therapies-next-gener/

Pipeline Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for potent pipeline drugs
http://www.reportsandreports.com/market-reports/pipeline-insight-multiple-sclerosis-risk-benefit-ratio-under-t/

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://www.reportsandreports.com/
http://reportsnreports.wordpress.com/

###
Contact
ReportsandReports
Akshata Patil
+1-888-989-8004
http://www.reportsandreports.com/
ContactContact
Categories